Ad
related to: fda approved drugs for leukemia- How ICLUSIG Works
Learn more about ICLUSIG and how
it may work as a treatment option.
- Support and Resources
Find info on resources
and our support program.
- How ICLUSIG Works
Search results
Results from the WOW.Com Content Network
Antileukemic drugs, anticancer drugs that are used to treat one or more types of leukemia, include: [1]. 6-Mercaptopurine; 6-Thioguanine; Arsenic trioxide; Asparaginase; Cladribine ...
In January 2023, the US Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. [19] In March 2024, FDA granted accelerated approval to zanubrutinib, in combination with obinutuzumab, for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. [20] [21]
Revumenib was approved for medical use in the United States in November 2024. [ 1 ] [ 3 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication . [ 4 ]
Nilotinib is used to treat Philadelphia chromosome (Ph+)-positive chronic myelogenous leukaemia. [3] [6] It is indicated for the treatment of newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase; [3] [5] adults with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia resistant to or intolerant to prior therapy that ...
[1] [11] In December 2023, the US Food and Drug Administration (FDA) expanded the indication for pirtobrutinib to include the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia. [7] [12] In the European Union, pirtobrutinib is indicated for the treatment of mantle cell lymphoma. [2]
The U.S. Food and Drug Administration (FDA) has approved imatinib as first-line treatment for Philadelphia chromosome-positive CML, both in adults and children. The drug is approved in multiple contexts of Philadelphia chromosome-positive CML, including after stem cell transplant, in blast crisis, and newly diagnosed. [12]
In July 2017, an FDA advisory committee unanimously recommended that the agency approve it to treat B cell acute lymphoblastic leukemia that did not respond adequately to other treatments or have relapsed. [14] [19] [20] In August 2017, the FDA granted approval for the use of tisagenlecleucel in people with acute lymphoblastic leukemia.
Imatinib remains a standard frontline TKI. Nilotinib and dasatinib are also approved by the FDA as frontline drugs, in June and October 2010, respectively. Four of these drugs, nilotinib, dasatinib, bosutinib and ponatinib are approved for the treatment of imatinib-resistant or intolerant CML.
Ad
related to: fda approved drugs for leukemia